PRAXIS PRECISION MEDICINES, INC. Restructuring and Related Cost, Incurred Cost
PRAXIS PRECISION MEDICINES, INC. (PRAX) reported Restructuring and Related Cost, Incurred Cost of $1.00 million for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-05.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostIncurredCost · last filed 2024-03-05
- PRAXIS PRECISION MEDICINES, INC. restructuring and related cost, incurred cost for the quarter ending 2022-12-31 was $0.00.
- PRAXIS PRECISION MEDICINES, INC. restructuring and related cost, incurred cost for the quarter ending 2022-09-30 was $0.00.
- PRAXIS PRECISION MEDICINES, INC. restructuring and related cost, incurred cost for the quarter ending 2022-06-30 was $1.00M.
- PRAXIS PRECISION MEDICINES, INC. restructuring and related cost, incurred cost for fiscal 2022 was $1.00M.
| Period end | Restructuring and Related Cost, Incurred Cost 3 month | Restructuring and Related Cost, Incurred Cost 6 month | Restructuring and Related Cost, Incurred Cost 9 month | Restructuring and Related Cost, Incurred Cost 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $0.00 derived: sum of 2 quarters · filed 2024-03-05 | $1.00M derived: sum of 3 quarters · filed 2024-03-05 | $1.00M 10-K · filed 2024-03-05 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $1.00M derived: sum of 2 quarters · filed 2023-11-07 | $1.00M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $1.00M 10-Q · filed 2023-08-09 | $1.00M 10-Q · filed 2023-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |